Q-omics provides the consensus-scored FIBP profile across patient tissues and cancer cell-line models. FIBP expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FIBP is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, FIBP RNA expression shows 19,172 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where FIBP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FIBP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FIBP survival associations across molecular data types. FIBP RNA expression shows survival associations in the most cancer types (25), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FIBP RNA expression–survival associations across cancer types. High FIBP expression shows unfavorable associations in ACC, KICH, MESO, LIHC, LAML and UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FIBP RNA expression.
This table summarizes FIBP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FIBP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FIBP shows higher tumor expression in HNSC, KIRC, COAD, BLCA, LIHC and LUSC. The HNSC box plot shows higher FIBP RNA expression in tumor versus normal tissue (log2 FC = +1.000, t-test p < 0.001).
This table shows molecular features associated with FIBP in patient tissues and cancer cell lines. In patient samples, FIBP shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FIBP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
